AboutZydus Pharmaceuticals USA
Zydus Pharmaceuticals (USA) Inc., located in Pennington, New Jersey, has come a long way since its first commercial launch in August 2005. The company currently offers more than 450 SKUs to the US market and is ranked the fifth largest unbranded generic corporation in the US based on dispensed prescriptions (IQVIA, NPA Audit, MAT March 2022). In 2017, Zydus acquired Sentynl Therapeutics Inc., a specialty pharmaceutical company based in Solana Beach, CA. This acquisition has helped Zydus to grow from a generic company focused on solid oral generics to a company that offers more complex dosage forms.
While Zydus has grown tremendously since it entered the US, the company is continuing to look for new ways to bring value to the US market. Zydus is aggressively pursuing franchises it does not exist in today to further its footprint in the lives of patients. The company has launched several products out of its oncology facility and plans on expanding its dermatology and injectable product lines.
With the strength and worldwide reputation of Zydus Lifesciences supporting the US division, Zydus is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505(b)(2) opportunities, it looks forward to great success in the coming years. To date, Zydus has filed over 120 drug master files (DMFs), received final USFDA approval on 286 Abbreviated New Drug Applications (ANDAs), received tentative USFDA approval on 31 ANDAs, and has 92 ANDAs pending approval with the USFDA. The company also has approximately 250 additional products in various stages of development.
Our Mission
Creating Healthier CommunitiesZydus is dedicated to life, in all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern for people in an effort to create healthier communities, globally.
A Vision That Unleashes ValueZydus shall be a leading global healthcare provider with a robust product pipeline; Opening up new pathways through innovation and quality excellence, we shall be a research-based company by the end of 2020.